←
Codiak BioSciences156 posts
Codiak BioSciences avatar

Codiak BioSciences

@codiakbio

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines. $CDAK

◷ Joined May 2016▧ 125 Photos and videos
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·7 Mar 2023

Through case studies based on successful process development, Matt Brown will present on the evolution of exosome manufacturing technology from batch to continuous and highlight further opportunities for integrated, continuous bioprocessing. See you at the CCP Summit!

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·31 Jan 2023

Recognizing Andrew Wood, who presented at the CMC Strategy Forum last week. His talk highlighted the evolution of Codiak’s approach to delivering oligonucleotides with exosomes & optimization strategies for surface-bound ASOs, including payload attachment and linker design.

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·20 Jan 2023

This week our CTO, Konstantin Konstantinov welcomed Professor Kenneth Witwer of Johns Hopkins University and President-elect of @IsevOrg to give a talk about EV biodistribution & immunogenicity with our team. Thanks to Professor Witwer for a compelling presentation and dialogue!

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·1 Dec 2022

Our CEO Doug Williams and our CFO Linda Bain participated in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference this week. Thanks to Evercore for a great conversation about our clinical-stage programs and our platform. https://t.co/vRIegt3EXF

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·10 Nov 2022

CEO Douglas Williams on the data we presented at SITC, and our ongoing Phase 1 clinical study of exoASO-STAT6, which is on track for data in the first half of 2023. https://t.co/ZSwtrpOx5l

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·10 Nov 2022

We presented very encouraging preclinical data on two of our programs, exoASO-STAT6 and exoASO-C/EBPβ, at SITC 2022. Our CSO, Sriram Sathy provides the high-level takeaways. https://t.co/ZSwtrpOx5l

0:17
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·14 Oct 2022

Recognizing Sriram Sathy for his presentation today at NIBIT on how we engineer our exosome therapeutics to reprogram tumor-associated myeloid cells.

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·12 Oct 2022

Our CSO, Sriram Sathyanarayanan, on the protection offered by our pan beta-coronavirus vaccine candidate, which based on this data, may limit the virus’ ability to mutate and evade protection. https://t.co/YgWG64Nso8

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·12 Oct 2022

Today we present preclinical data at the Vaccines Summit 2022 in Washington DC, showing our pan beta-coronavirus vaccine candidate protects against multiple known variants of SARS-CoV-2 and seven sarbecoviruses circulating in bats. https://t.co/YgWG64Nso8

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·10 Oct 2022

Long-term stability is a critical issue when it comes to therapeutics both clinically and commercially, and Lisa Jacob, our Scientist I, will present how we’ve achieved this with our exosome constructs.

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·7 Oct 2022

Konstantin Konstantinov and Aaron Noyes will both present next week at the ICB V conference in Barcelona, highlighting how exosomes are helping lead the way as one of the newest innovations in integrated continuous processing of bionanoparticles.

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·5 Oct 2022

At SITC, we’ll present new preclinical data on two of our systemically administered exosome therapeutic candidates which target macrophages and have previously demonstrated potent monotherapy activity in preclinical models. We’ll see you in Boston! https://t.co/kDuCadxipi

Post attachment
Codiak BioSciences avatar
Codiak BioSciences@codiakbio·30 Sep 2022

Dalia Burzyn will present next week on exoASO-STAT6, a novel investigational therapeutic candidate that induces reprogramming of tumor-associated macrophages, promotes CD8 T-cell mediated adaptive immune responses & shows potent monotherapy activity in several preclinical models.

Post attachment